Clinical Trials Logo

Filter by:
NCT ID: NCT04146493 Completed - Clinical trials for Cardiovascular Diseases

Heparin-Binding Protein and Heparins

HepHep
Start date: April 1, 2019
Phase:
Study type: Observational

Heparin-Binding protein is a protein from primary and secretory granluae of white blood cells. It is released when white blood cells become activated and has been advocated as a biomarker for sepsis. The aim of this study is to find out if Heparins in clinical doses can change the level of Heparin-binding protein in plasma.

NCT ID: NCT04144842 Completed - Neoplasms Clinical Trials

Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017

Start date: December 3, 2019
Phase: Phase 1
Study type: Interventional

The aim of the study is to assess the safety and tolerability of increasing doses of ATOR-1017 when administered as repeated intravenous infusions to patients with advanced and/or refractory solid malignancies.

NCT ID: NCT04143503 Completed - Critical Illness Clinical Trials

Observational Cohort Study on the Use of Parenteral Nutrition and Clinical Outcomes in Adult Critically Ill Patients

Start date: November 5, 2019
Phase:
Study type: Observational

The aim of this study is to characterise the use of clinical nutrition support, especially of parenteral nutrition that is administered directly into a vein, in adult patients with critical illness. The study wants to assess nutritional balance (that means the ratio of calories and protein prescribed to calories and protein actually received). Furthermore, it wants to evaluate whether the nutrition received has influence on the patients' clinical outcome, with focus on measures of physical function, such as capability of conducting daily living activities. As the study is "observational", no specific medications or treatments will be provided as part of the study to the patients. Study patients will be observed during their stay on an intensive care unit, for a maximum duration of 15 days. Furthermore, questions on the well-being of the patients will be asked via telephone interviews 30 and 90 days after their admission to the intensive care unit. Data of approximately 1250 patients will be collected and evaluated in this study, from approximately 100 hospitals in 11 European countries (Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, Poland, Spain, Sweden and United Kingdom).

NCT ID: NCT04141072 Completed - Kidney Diseases Clinical Trials

Shrunken Pore Syndrome: a Retrospective, Single Center, Cohort Study

Start date: January 1, 2010
Phase:
Study type: Observational [Patient Registry]

To study the impact a difference in renal clearance of small and large molecules has on long-term survival.

NCT ID: NCT04137211 Completed - Healthy Adults Clinical Trials

Acute Effects of Sitting and Physical Activity on Brain Health

Start date: May 13, 2019
Phase: N/A
Study type: Interventional

The specific aim of this study is to understand how a working day composed of prolonged sitting, sitting regularly interrupted by light aerobic exercise or resistance exercise affects an important mechanism underpinning healthy brain functions, namely cerebral blood flow. It is primarily focused on investigating these effects in ecologically valid conditions, i.e. activity patterns that closely resemble a typical day at the office.

NCT ID: NCT04136184 Completed - Clinical trials for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Start date: January 15, 2020
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of eplontersen after administration for 65 weeks to patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN), as compared to the NEURO-TTR trial (NCT01737398). For more information, please visit http://www.neuro-ttransform.com/.

NCT ID: NCT04134130 Completed - Clinical trials for Prostate Cancer Recurrent

The Role of Follicle Stimulating Hormone in Advanced Prostate Cancer

Start date: September 16, 2019
Phase: N/A
Study type: Interventional

In order to elucidate if FSH can have testosterone like effects, samples from young, non-smoking healthy volunteers, with normal body mass index, and with pharmacologically induced gonadotropin deficiency will be studied regarding their capacity to induce prostate specific antigen (PSA), which normally is regulated by testosterone.

NCT ID: NCT04131140 Completed - Decision Making Clinical Trials

Organ Donation and End-of-life Decisions

Start date: January 1, 2014
Phase:
Study type: Observational [Patient Registry]

Variation in organ donation after brain death (DBD) per million population varies markedly between countries, within country regions, between and within intensive care units (ICU). These circumstances also apply to end-of-life decisions in the ICU. The investigators studied all ICU deaths in Sweden between 2014-2017 in ICUs that, as routine, registered treatment plan (no treatment limitation and/or treatment limitation) and DBD. The investigators hypothesized that ICUs with high proportion of treatment limitation (withholding or withdrawing life sustaining treatment) also had less proportion of DBD.

NCT ID: NCT04129736 Completed - Clinical trials for Multiple Sclerosis, Pharmacokinetics

Teriflunomide Concentration in Serum and Cerebrospinal Fluid From Patients With Multiple Sclerosis

Start date: October 10, 2019
Phase: Phase 4
Study type: Interventional

Serum and cerebrospinal fluid will be obtained from 20 patients with relapsing-remitting multiple sclerosis treated with teriflunomide tablets 14 mg daily

NCT ID: NCT04129658 Completed - Drug Use Clinical Trials

Heart Failure in Southern Sweden

HISS
Start date: May 26, 2021
Phase:
Study type: Observational [Patient Registry]

The aim of the study is to optimize diagnosis and treatment for patients with heart failure in Swedish primary care. Patient with the diagnose heart failure registered in the electronic medical record (EMR) at seventeen primary health care centers (PHCCs) will be invited to to participate in the study. Blood testing and electrocardiography will be performed. Data on diagnosis and medical treatment will be collected from the EMR. An educational visit with a cardiologist will be performed at the PHCC, in order to discuss evidence-based diagnoses and treatment of heart failure. Data on drug therapy and health care consumption will be collected after six and twelve months.